Introduction {#sec1-0300060518760435}
============

Ventilator-associated pneumonia (VAP) is defined as pneumonia occurring in mechanically ventilated patients that develops at least 48 hours after introduction of mechanical ventilation. VAP is the most common cause of device-associated healthcare-associated infections in the paediatric intensive care unit in developing areas, with an incidence from 9.0 to 30.8 per 1000 ventilator-days. VAP is associated with an increased risk of death and prolonged duration of mechanical ventilation.^[@bibr1-0300060518760435][@bibr2-0300060518760435]--[@bibr3-0300060518760435]^ Antibiotics are important in VAP treatment, but it is currently challenged by multidrug-resistant (MDR) bacteria. Gram-negative bacteria, such as *Acinetobacter baumannii,* are the main pathogens in children with VAP, and they are resistant to many broad-spectrum antibiotics, such as carbapenems.^[@bibr1-0300060518760435]^

Tigecycline is a tetracycline class antibacterial that is indicated for patients aged 18 years and older. Tigecycline is prescribed for complicated skin, skin structure, and intra-abdominal infections and community-acquired bacterial pneumonia, especially in those infected by MDR bacteria.^[@bibr4-0300060518760435]^ A phase III, multicentre, randomized, double-blind study that included 945 adults showed that tigecycline was not superior to imipenem/cilastatin in patients with VAP regarding clinical response.^[@bibr5-0300060518760435]^ However, tigecycline is still a choice in critically ill children when alternatives are unavailable because of its wide antibacterial spectrum.

Since tigecycline was approved by the state food and drug administration in early 2012, it may be prescribed in consideration of the risk-benefit ratio when no alternative antibacterial drugs are available in critically ill children in our hospital. In this study, we retrospectively reviewed tigecycline therapy in children with VAP in the past 5 years in our hospital, and investigated its efficacy and safety.

Methods {#sec2-0300060518760435}
=======

This was a retrospective review study that was conducted in a children's hospital affiliated to Zhejiang University, School of Medicine in China between May 1, 2012 and May 1, 2017. This hospital consists of 1900 beds and only admits patients aged younger than 18 years. This retrospective study was approved by the Medical Ethics Committee of Zhejiang University School of Medicine Children's Hospital (approval number: 2017-IRB-038). Data collection of the patients was verbally approved by the patients' parents.

Selection of patients and study design {#sec3-0300060518760435}
--------------------------------------

All patients who received tigecycline for VAP were identified by the hospital information system and were enrolled if patients received at least 2 days (4 doses) of administration of tigecycline. A custom made MS excel database (Microsoft Excel 2007) of patients was created to record demographic and medical data. Demographic data included age, sex, and weight, and medical data included the following characteristics: medical history (underlying disease), dose and duration of tigecycline therapy, information of other antimicrobial agents (prior or concomitant to tigecycline treatment), invasive procedures (i.e., deep venous catheterization), and laboratory tests. Laboratory tests comprised counts of leucocytes and neutrophilic granulocytes, C-reactive protein levels, procalcitonin levels, microorganisms (results of blood/bronchial or other cultures and antimicrobial susceptibility testing), biochemistry (aspartate transaminase, alanine aminotransferase, bilirubin, creatinine, and amylase levels), and coagulation (activated partial thromboplastin time and fibrinogen). All of these data were collected at the time of starting and ending tigecycline therapy.

Tigecycline administration {#sec4-0300060518760435}
--------------------------

Tigecycline (Pfizer Inc., New York, NY, USA) vials were used, each containing 50 mg of dry powder. Tigecycline was administered intravenously after being dissolved in normal saline and infused over 1 hour (according to its instruction).

### Definitions {#sec5-0300060518760435}

According to the Centers for Disease Control and Prevention, VAP was diagnosed by the presence of new or progressive radiographic evidence of a pulmonary infiltrate for longer than 48 hours after initiation of mechanical ventilation, and the presence of clinical signs and symptoms of pneumonia (fever, purulent sputum, leukocytosis, oxygen desaturation).^[@bibr6-0300060518760435]^ The purpose of tigecycline treatment was considered empiric or targeted. The term empiric indicated that administration was started based on surveillance data or no response to other antimicrobials, while targeted indicated that the patient was treated according an antimicrobial susceptibility report. The course of intravenous tigecycline administration was defined as a period of continuous tigecycline administration in the same patient. Bacteria resistant to at least three antimicrobial agents of different antimicrobial categories were considered to be MDR. Antimicrobial susceptibility testing of bacteria was performed based on the clinical laboratory standards institute guidelines and the break points for tigecycline as defined by the American Food and Drug Administration. The tigecycline minimum inhibitory concentrations (MICs) for *Acinetobacter* in our hospital are susceptible (MIC = 2 µg/mL), intermediate (MIC =4 µg/mL), and resistance (MIC ≥ 8 µg/mL).

### Evaluation of outcome and adverse events {#sec6-0300060518760435}

Resolution of clinical manifestation and microbial eradication were the primary outcomes that were evaluated to determine tigecycline efficacy. "Cured" was considered when clinical and microbiological results returned to normal and no other antibiotics were required. If patients improved and required antimicrobial degradation, they were considered as "improved". Patients who died and who had persistent clinical signs and symptoms of VAP were considered as failure of treatment. The in-hospital mortality and tigecycline toxicity were recorded in all of the patients. Occurrence of teeth discoloration (yellow-grey-brown) was confirmed by a telephone survey for survivors.

Statistical analysis {#sec7-0300060518760435}
--------------------

All statistical analysis was performed using IBM SPSS Statistics, version 22.0 (IBM Corp., Armonk, NY, USA). The chi-square test or Fisher's exact test for small samples was used for categorical variables when necessary. The Student's t-test was used for comparison of continuous variables.^[@bibr7-0300060518760435]^ A p value less than 0.05 was considered to be statistically significant.

Results {#sec8-0300060518760435}
=======

Characteristics of patients {#sec9-0300060518760435}
---------------------------

Twenty-four children (20 girls) with a median age of 8 months (range, 27 days to 6 years and 9 months) were treated with tigecycline for VAP between May 1, 2012 and May 1, 2017. All of the patients received tigecycline treatment for at least 2 days (4 doses) and no patients were excluded. The median time of mechanical ventilation and intensive care unit (ICU) length of stay were 21.5 days (range, 5--86 days) and 45 days (range, 6--86 days), respectively. In-hospital mortality was 41.7% (10/24). Two of the 24 (8.3%) patients had all medical support withdrawn in consideration of disease severity and financial problems. Three deaths were attributable to severe infection. Congenital heart disease comprised over half (15/24) of the primary disease. Locations of infection comprised blood and catheters. A total of 19 patients received cardiopulmonary bypass surgery (15/24), closed thoracic drainage (1/24), pelvic drainage (1/24), oesophagogastrostomy (1/24), and skin debridement (1/24). The characteristics of the patients are shown in [Table 1](#table1-0300060518760435){ref-type="table"}.

###### 

Patients' characteristics.

![](10.1177_0300060518760435-table1)

  No.   Age (y/mo/d)   Sex (M/F)   Underlying disease   Infection            Invasive procedure            Mechanical ventilation time (d)   ICU stay (d)   Hospital outcome   Cause of death (yes/no)
  ----- -------------- ----------- -------------------- -------------------- ----------------------------- --------------------------------- -------------- ------------------ -------------------------
  1     8 mo, 17 d     M           CHD                  VAP                  Open heart surgery with CPB   38                                62             Cured              No
  2     10 mo, 5 d     F           CHD                  VAP+catheter         Open heart surgery with CPB   12                                33             Cured              No
  3     2 mo, 28 d     M           CHD                  VAP                  Open heart surgery with CPB   43                                56             Cured              No
  4     8 mo, 17 d     M           CHD                  VAP                  Open heart surgery with CPB   20                                55             Cured              No
  5     3 y, 7 mo      M           CHD                  VAP                  Open heart surgery with CPB   40                                60             Died               No
  6     3 y, 8 mo      M           CHD                  VAP                  Open heart surgery with CPB   40                                60             Died               No
  7     6 mo, 17 d     F           CHD                  VAP                  Open heart surgery with CPB   41                                52             Cured              No
  8     1 y, 9 mo      M           Drowning             VAP                  None                          11                                14             Died               No
  9     1 y, 8 mo      M           CHD                  VAP+blood            Open heart surgery with CPB   40                                56             Improved           No
  10    5 y, 4 mo      F           CHD                  VAP+blood            Open heart surgery with CPB   11                                57             Cured              No
  11    6 y, 9 mo      M           CAP                  VAP                  Closed thoracic drainage      22                                23             Died               Yes
  12    8 mo, 18 d     M           CHD                  VAP                  Open heart surgery with CPB   15                                22             Died               No
  13    4 mo, 16 d     M           BPD                  VAP+urinary tract    Pelvic drainage               16                                38             Cured              No
  14    1 mo, 22 d     M           CHD                  VAP                  Open heart surgery with CPB   12                                19             Cured              No
  15    27 d           M           CEA                  VAP                  Oesophagogastrostomy          15                                24             Died               No
  16    4 mo, 28 d     F           CHD                  VAP+blood            Open heart surgery with CPB   86                                86             Improved           No
  17    1 mo, 24 d     M           CHD                  VAP+blood            Open heart surgery with CPB   36                                36             Died               No
  18    7 mo, 11 d     M           CHD                  VAP+blood+catheter   Open heart surgery with CPB   44                                44             Abandoned          No
  19    4 y, 6 mo      F           Burn                 VAP+blood            Skin debridement              11                                73             Improved           No
  20    4 y, 4 mo      F           CHD                  VAP+catheter         Open heart surgery with CPB   32                                47             Cured              No
  21    2 y, 3 mo      M           HPS                  VAP+blood            None                          21                                24             Died               No
  22    2 mo, 11 d     F           Sepsis               VAP+blood            None                          6                                 6              Abandoned          No
  23    4 mo, 14 d     F           Cerebral dysplasia   VAP+blood            None                          27                                46             Died               Yes
  24    1 mo           M           HPS                  VAP+blood            None                          5                                 9              Died               Yes

y: years; mo: month; d: days; M: male; F: female; VAP: ventilator-associated pneumonia; ICU: intensive care unit; CHD: congenital heart disease; CAP: community-associated pneumonia; BPD: bronchopulmonary dysplasia;

CPB: cardiopulmonary bypass; CEA: congenital oesophageal atresia; HPS: haemophagocytic syndrome.

Cause of death refers to whether infection is the leading cause of death.

Use of tigecycline, prior drugs, and concomitant drugs {#sec10-0300060518760435}
------------------------------------------------------

Use of tigecycline, previous drugs, and concomitant drugs is shown in [Table 2.](#table2-0300060518760435){ref-type="table"}A total of 70.8% (17/24) of patients received a loading dose of 1.5 mg/kg, followed by 1 mg/kg every 12 hours. A total of 25% (6/24) of patients were provided a loading dose of 2 mg/kg and there was no loading dose in one patient. Most (16/24) prescriptions were targeted, according to spectrum culture results, and others (8/24) were empirically used in consideration of the clinical condition. Prior drugs, such as sulperazone, piperacillin/tazobactam, and meropenem, before tigecycline administration were administered and failed to lead to any improvement. The median duration of previous drugs was 7.5 days (range, 2--26 days). Sulperazone (13/22) was the most frequently used concomitant drug, followed by piperacillin/tazobactam (5/22). The median duration of tigecycline therapy was 10.75 days (range, 3--21.5 days). The remaining two patients received tigecycline alone.

###### 

Use of tigecycline, concomitant drugs, prior drugs, isolated pathogens, and efficacy.

![](10.1177_0300060518760435-table2)

  No.   L dose   M dose   Type of therapy   Prior drug    Duration of prior drug (days)   Concomitant drug   LOT (days)   Isolate (tigecycline susceptibility)                        MO   CO
  ----- -------- -------- ----------------- ------------- ------------------------------- ------------------ ------------ ----------------------------------------------------------- ---- -----------
  1     1.5      1        Targeted          SPZ           15                              No                 20.5         *Acinetobacter baumannii* (NA)                              P    Improved
  2     1.5      1        Targeted          MEM           7                               VMC+SPZ            7.5          *A. baumannii* (NA)                                         P    Failed
  3     1.5      1        Empirical         LFX           12                              PRC/TZB            21.5         Negative                                                    P    Improved
  4     1.5      1        Empirical         SPZ           6                               PRC/TZB            21.5         *Burkholderia cepacia* (NA),*Pseudomonas aeruginosa* (NA)   P    Improved
  5     1.5      1        Targeted          PRC/TZB       4                               SPZ                10           *A. baumannii* (S)                                          P    Failed
  6     1.5      1        Targeted          SPZ           26                              LFX                8            *A. baumannii* (S)                                          P    Failed
  7     1.5      1        Targeted          SPZ           6                               SPZ                19.5         *A. baumannii* (S)                                          E    Failed
  8     2        1        Targeted          MEM           3                               SPZ                6.5          *Klebsiella pneumoniae* (I), *Proteus mirabilis* (R)        P    Failed
  9     1.5      1        Empirical         SPZ           8                               PRC/TZB            8.5          *B. cepacia* (R)                                            P    Failed
  10    1.5      1        Empirical         LFX           16                              PRC/TZB            16           Negative                                                    P    Improved
  11    2        1        Empirical         PRC/TZB       2                               SPZ                14.5         Negative                                                    P    Failed
  12    1.5      1        Targeted          SPZ           6                               PRC/TZB            3.5          *A. baumannii* (S)                                          E    Died
  13    2        1        Empirical         MEM           13                              MEM                11.5         Negative                                                    P    Improved
  14    1.5      1        Targeted          SPZ           3                               SPZ                13.5         *A. baumannii* (I)                                          E    Improved
  15    1.5      1        Targeted          SPZ           15                              SPZ                4.5          *A. baumannii* (I)                                          E    Died
  16    1.5      1        Empirical         SPZ           12                              SPZ                17.5         *A. baumannii* (S)                                          P    Improved
  17    1.5      1        Targeted          PRC/TZB       3                               SPZ                8.5          *A. baumannii* (S)                                          E    Failed
  18    1.5      1        Targeted          PRC/TZB+LFX   5                               SPZ+AMK            17.5         *A. baumannii* (S)                                          P    Failed
  19    1.5      1        Targeted          PRC/TZB       11                              SPZ                18.5         *A. baumannii* (I)                                          P    Improved
  20    1.5      1        Targeted          MEM           12                              SPZ                20.5         *A. baumannii* (R)                                          P    Failed
  21    2        1        Targeted          MEM           26                              SPZ+LZD            6.5          *A. baumannii* (S)                                          E    Died
  22    0        1        Targeted          TIN           4                               ETM                3            *Stenotrophomonas maltophilia* (S)                          P    Abandoned
  23    2        1        Targeted          LFX           20                              no                 4.5          *Chryseobacterium meningosepticum* (I)                      P    Died
  24    2        1        Empirical         MEM           4                               MEM                5            *K. oxytoca* (S)                                            P    Died

L dose: loading dose (mg/kg); M dose: maintenance dose (mg/kg every 12 hours); LOT: length of treatment; S: susceptible; I: intermediate; R: resistance; NA: not applicable; MO: microbiological outcome; CO: clinical outcome; P: persistence; E: eradication; VMC: vancomycin; TIN: tienam; SPZ: sulperazone; PRC/TZB: piperacillin/tazobactam; LFX: levofloxacin; MEM: meropenem; LZD: linezolid; ETM: erythromycin; AMK: amikacin

Isolated pathogen {#sec11-0300060518760435}
-----------------

[Table 2](#table2-0300060518760435){ref-type="table"} shows that there were 18 pathogens isolated in 16 patients and all were gram-negative bacteria. *A. baumannii* was the predominant microbiology and comprised 87.5% (14/16). Most of the *A. baumannii* (11) pathogens were susceptible to tigecycline. Only one strain of *A. baumannii* was resistant to tigecycline and two strains behaved with intermediate susceptibility to tigecycline. However, *A. baumannii* in case 5 developed resistance after 7 days of tigecycline administration.

Tigecycline efficacy {#sec12-0300060518760435}
--------------------

A total of 41.6% (10/24) of patients showed failure of tigecycline therapy, 20.8% (5/24) of patients died, and one patient abandoned this therapy because of critical illness. Eight patients achieved clinical improvement in total. In targeted therapy cases, 37.5% (6/16) of patients were pathogen-negative at the end of treatment. These results are shown in [Table 2](#table2-0300060518760435){ref-type="table"}.

Adverse events {#sec13-0300060518760435}
--------------

Because all of the patients were ventilated, data on nausea or vomiting were not available. There were no reports of diarrhoea, increased levels of aspartate transaminase or bilirubin, or a decrease in fibrinogen concentrations. No survivors developed teeth discoloration when talked to by telephone.

Discussion {#sec14-0300060518760435}
==========

To the best of our knowledge, this is the first report of tigecycline use in children with VAP. Although tigecycline has a broad antibacterial spectrum, it is not recommended for VAP according its instructions.^[@bibr4-0300060518760435]^ There is no reference about the use of tigecycline in VAP children and the efficacy and dosage of tigecycline in VAP adults is still controversial.^[@bibr5-0300060518760435],[@bibr8-0300060518760435]^

The results of our study were not encouraging. The overall improvement rate was 33% (8/24), the mortality rate was 20.8% (5/24), and the microbiological eradication rate was 30% (6/20). According to a cohort study in Pakistan, the overall mortality of children with VAP was 23%.^[@bibr9-0300060518760435]^ Another study on tigecycline that was conducted in an adult population reported an improvement rate of 37.1% and a mortality rate of 13.1%.^[@bibr5-0300060518760435]^ Therefore, our patients did not appear to benefit from tigecycline administration, which might be explained from two aspects.

One reason for this lack of benefit is that tigecycline was off-label in children with VAP. Tigecycline was prescribed only in severe infections as a salvage therapy and initiation of tigecycline was later than that in adults, as reported in other studies.^[@bibr8-0300060518760435]^ In fact, only a small portion of deaths were directly attributable to severe infection in our study, and other causes included multi-organ dysfunction or irreversible brain damage due to drowning. A similar result was concluded in a study that included 13 patients with severe infection who had tigecycline treatment.^[@bibr10-0300060518760435]^ Furthermore, many patients had other severe infections, such as blood stream infection and catheter-related infection. McGovern et al found that tigecycline had no advantage in treating patients with VAP combined with sepsis, and that it even might increase mortality.^[@bibr11-0300060518760435]^ In the real clinical situation, a patient with multiple severe infections usually has greater severity and a higher propensity to organ dysfunction, treatment failure, and death.

Currently, there is no consensus on the use of tigecycline for children with VAP, and the appropriate dosage of tigecycline remains unclear.^[@bibr12-0300060518760435]^ The only available reference for tigecycline use in children recommended 1.2 mg/kg every 12 hours in children aged 8 to 11 years with complicated intra-abdominal infection, complicated skin and skin structure infections, and community-acquired pneumonia.^[@bibr13-0300060518760435]^ Studies that involved the adult population with VAP showed that a regular dosage may not have an effect and a higher dosage (150--200 mg/d) was usually recommended to achieve better clinical outcomes and microbiological eradication.^[@bibr5-0300060518760435],[@bibr14-0300060518760435]^ All patients in our study were younger than 8 years, with the youngest child was aged only 27 days. For these patients, tigecycline is not indicated according to drug instructions. Additionally, a conservative dosage (loading dosage of 1.5--2 mg/kg, maintenance dosage of 1.0 mg/kg every 12 hours) was used in consideration of any conceivable adverse events, such as liver or kidney function damage. Therefore, future studies are required to determine an appropriate dosage for children with VAP.

All pathogens that were isolated were gram-negative bacteria and *A. baumannii* was the predominant pathogen in our study. This finding is in line with recent research showing that *A. baumannii* is one of the major pathogens in VAP.^[@bibr1-0300060518760435],[@bibr15-0300060518760435]^ As an opportunistic pathogen, *A. baumannii* often infects those who are seriously ill, those compromised by surgical procedures, those with severe immunosuppression, or those with invasive life support instruments, such as mechanical ventilation and surgical drainage.^[@bibr16-0300060518760435]^ MDR is easily developed because of its unique mechanisms. In our patients, there were at least two of the following risk factors: mechanical ventilation, surgical procedures, severe immunosuppression, and surgical drainage. The MIC confirmed that all documented cases of *A baumannii* were MDR with resistance to carbapenems, and one patient developed resistance to tigecycline during therapy. One report from Turkey showed that the rate of tigecycline-resistant *A. baumannii* could be as high as 25.8% in patients with VAP.^[@bibr17-0300060518760435]^ Therefore, tigecycline prescription should carried out with more caution to abate drug resistance, and microbiology results may be necessary.

In most paediatric cases in our study, tigecycline was combined with other antimicrobial regimens and sulperazone was a common choice. This finding is in line with recent reports on tigecycline use in children with serious infection.^[@bibr10-0300060518760435],[@bibr18-0300060518760435]^ A total of 14 multinational, randomized (open-label or double-blind), and active-controlled (except for one) phase III and IV studies suggested that with appropriate monitoring, tigecycline may be useful for *Acinetobacter* infections alone or in combination with other anti-infective agents when other therapies are not suitable.^[@bibr19-0300060518760435]^ Moreover, a drug-sensitive test demonstrated that tigecycline in combination with cefoperazone-sulbactam appeared to be an ideal option in MDR *A. baumannii* treatment.^[@bibr20-0300060518760435]^

Possible adverse events associated with tigecycline in children include nausea, vomiting, diarrhoea,^[@bibr13-0300060518760435]^ delay of neutrophil engraftment,^[@bibr21-0300060518760435]^ and acute pancreatitis.^[@bibr22-0300060518760435]^ All of the patients in our study were ventilated and critically ill, and assessing nausea and vomiting was difficult. However, there was no discontinuation or dose reduction of tigecycline due to adverse events in our case series, such as diarrhoea, elevated aspartate transaminase or bilirubin levels, and a decrease in fibrinogen levels. In a previous study, adverse events in adults with VAP who received a higher dosage of tigecycline than recommended (150 or 200 mg as a loading dose followed by 75 or 100 mg, respectively) were mild to moderate and were tolerable in general.^[@bibr14-0300060518760435]^

Definite conclusions on the efficacy and safety of tigecycline cannot be drawn based on our observational case series study. Our study was subject to selection bias and the clinical outcome may have been attributable to a temporal trend (e.g., not the effect of tigecycline). Furthermore, the concomitant use of other antibiotics makes interpretation of the results more challenging.^[@bibr23-0300060518760435][@bibr24-0300060518760435][@bibr25-0300060518760435]--[@bibr26-0300060518760435]^ However, this observational study provides preliminary experience on salvage therapy with tigecycline in children with VAP.

In conclusion, tigecycline combined with other agents as salvage therapy in children with VAP is feasible and tolerable. However, until more data from randomized, controlled trials are available, tigecycline should be used in children with VAP when alternatives are limited, and the microbiological results should be considered.
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